Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

A legfontosabb adatok

Ki végzi
Novartis Pharmaceuticals
Hol
Burkina Faso, Elefántcsontpart, Kenya, Kongó – Kinshasa, Mozambik, Ruanda és Uganda9 helyszín, 7 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
254 fő vett részt
Kezdés
2022. márc. 7.
Befejezés
2025. aug. 20.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Cipargamin
  • IV Artesunate
  • Coartem
A regiszteradat frissítve
2026. április 9.

Ki vehet részt

Életkor
6 hónap – 100 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Cohort 1: Participants aged ≥ 12 years with moderately severe malaria as defined in (prostration and/or repeated vomiting) without presence of other signs of severe malaria (and with high P. falciparum parasitemia (60,000-250,000 parasites per µl); Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined in modified version of WHO criteria and P. falciparum parasite count of ≥ 5000 per µl; Cohort 2: Participants aged ≥ 12 years; Cohort 3: Participants aged 6 - < 12 years; Cohort 4: Participants aged 2 - < 6 years; Cohort 5: Participants aged ≥ 6 months - < 2 years

Ki nem vehet részt

  • Treatment with quinine or artemisinin derivative or any other antimalarial drug or any antibiotic with known antimalarial activity within 12 hours of screening
  • Known underlying illness, surgical or medical condition, which is not related to ongoing event of severe malaria and which might jeopardize the participant's health in case of participation in the study or which might alter the distribution, metabolism or excretion of study treatment. For example:; neurological or neurodegenerative disorders,; cardiac, renal, or hepatic disease, diabetes,; epilepsy, cerebral palsy,; known or suspected to be HIV-1 positive and/or receiving antiretroviral treatment; malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases; known or suspected cases of active infections or concurrent febrile illness such as TB, Typhoid, COVID-19 etc; Additional exclusion criteria are as follows:
  • Mixed Plasmodium infections
  • ALT > 5 x the upper limit of normal range (ULN), regardless the level of total bilirubin
  • Total bilirubin is > 3 mg/dL
  • Signs/symptoms of severe malnutrition in general accordance with WHO guidelines:; Under 18 years: <-3 Z-scores of WHO growth standard for weight-for-height/length (in children < 5 years) or BMI for age (5-18 years), or very low mid-upper arm circumference (MUAC < 115 mm in children < 12 years, < 160mm 12-18 years), or bilateral pitting edema; Over 18 years: BMI < 16 kg/m2 or MUAC < 160mm or bilateral pitting edema
  • Body weight of < 35 kg or >75 kg
  • Body weight of < 35 kg or >75 kg
  • Participants diagnosed as moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria
  • Body weight of < 5 kg
  • Participants diagnosed as moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria

Hol van ez a vizsgálat?

7 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.

A teljes eredeti leírásKevesebb

The study also intended to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe malaria.

Severe malaria is a medical emergency and is affecting primarily young children in Africa. Injectable artesunate is the standard of care for the treatment of severe malaria and is highly efficacious. However, the spread of artemisinin-resistance in Plasmodium falciparum in Asian countries poses a threat for future treatment of patients with this life-threatening disease. To mitigate this risk, there is a need for another drug in malaria-endemic countries. Cipargamin treatment results in rapid clearance of parasites, including artemisinin-resistant parasites.

A vizsgálat 3 csoportja

  • IV Cipargamin 20 mgA vizsgált kezelés

    Participants received intravenous cipargamin 20 mg, as a minimum of two doses every 24 hours, not exceeding 3 doses followed by oral medication (Coartem®, twice daily \[b.i.d.\] for 3 days).

    Kezelés: Cipargamin és Coartem

  • IV Cipargamin 40 mgA vizsgált kezelés

    Participants received intravenous cipargamin 40 mg, as a minimum of two doses every 24 hours, not exceeding 3 doses followed by oral medication (Coartem®, twice daily \[b.i.d.\] for 3 days).

    Kezelés: Cipargamin és Coartem

  • IV ArtesunateMár használt kezelés, összehasonlításként

    Participants received IV artesunate according to label and followed by oral medication (Coartem® b.i.d. for 3 days).

    Kezelés: IV Artesunate és Coartem

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium Falciparum Malaria (KARISMA - KAE609's Role In Severe Malaria)
A regiszteradat frissítve
2026. április 9.